Author

J. E. Koblinski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

B. Hu· 2 shared M. O. Idowu· 2 shared M. Puchalapalli· 2 shared A. Anderson· 1 shared B. Ding· 1 shared B. E. Windle· 1 shared C. Edwards· 1 shared E. J. Peterson· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Hu

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis

K. K. Chougoni, V. Neely, B. Ding, E. Oduah, V. Lam, B. Hu, J. E. Koblinski, B. E. Windle, S. P. Deb, S. Deb, S. K. Radhakrishnan, H. Harada, S. R. Grossman

This study shows proteasome inhibitors are more effective against NSCLC cells with mutant p53 by inducing oxidative stress and mitochondrial apoptosis, suggesting a new therapeutic strategy.

bioRxiv · Feb 22, 2024Cancer Biology

Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer

J. D. Hampton, E. J. Peterson, S. J. Katner, T. H. Turner, M. A. Alzubi, J. C. Harrell, M. G. Dozmorov, P. J. Gigliotti, V. Kraskauskiene, M. Shende, M. O. Idowu, M. Puchalapalli, B. Hu, L. Litovchick, E. Katsuta, , J. E. Koblinski

This study identifies sulfated glycosaminoglycan (sGAG) levels as a biomarker predicting response to Triplatin in triple-negative breast cancer (TNBC), showing improved efficacy compared to carboplatin in sGAG-high tumors.

bioRxiv · May 5, 2021Pharmacology & Toxicology

Syndecan-1 facilitates breast cancer metastasis to the brain

M. R. Sayyad, M. Puchalapalli, N. G. Vergara, S. Mosticone Wangensteen, M. Moore, L. Mu, C. Edwards, A. Anderson, S. Kall, M. Sullivan, M. Dozmorov, J. Singh, M. O. Idowu, J. E. Koblinski

This study shows that syndecan-1 promotes breast cancer metastasis to the brain by enhancing cell migration across the blood-brain barrier and altering cytokine secretion.

bioRxiv · Mar 5, 2019Cancer Biology